The companies entered into a definitive agreement for the $4.9 billion acquisition in January. The deal will support Stryker’s neurovascular business.
Inari was founded in 2011 and makes products for VTE clot removal without thrombolytic drugs.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
